PARAGANGLION NEOPLASM MALIGNANT

PARAGANGLION NEOPLASM MALIGNANT was reported 30 times

PARAGANGLION NEOPLASM MALIGNANT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Catecholamine Synthesis Inhibitor [EPC] 1 0.0123
1 Neonatal Fc Receptor Blocker [EPC] 1 0.0002
2 Thiazide-like Diuretic [EPC] 2 0.0000
3 Alkylating Drug [EPC] 10 0.0000
4 alpha-Adrenergic Blocker [EPC] 4 0.0000
5 Opioid Agonist [EPC] 4 0.0000
6 beta-Adrenergic Blocker [EPC] 4 0.0000
7 Topoisomerase Inhibitor [EPC] 1 0.0000
8 Aminosalicylate [EPC] 1 0.0000
9 RANK Ligand Inhibitor [EPC] 2 0.0000
10 Kinase Inhibitor [EPC] 5 0.0000
11 Nucleoside Metabolic Inhibitor [EPC] 2 0.0000
12 Janus Kinase Inhibitor [EPC] 1 0.0000
13 Interferon beta [EPC] 1 0.0000
14 Thiazide Diuretic [EPC] 1 0.0000
15 Platinum-based Drug [EPC] 1 0.0000
16 Dihydropyridine Calcium Channel Blocker [EPC] 1 0.0000
17 Vitamin C [EPC] 1 0.0000
18 Corticosteroid [EPC] 3 0.0000
19 Insulin Analog [EPC] 1 0.0000
20 Nonsteroidal Anti-inflammatory Drug [EPC] 2 0.0000